Mangalore Refinery and Petrochemicals (MRPL) has been granted a US patent for the method of preparation of iso-Butyl Benzene (i-BB), recognizing the novelty and technical excellence of the in-house developed process. This marks a major step forward in establishing MRPL's global footprint in pharmaceutical technology innovation, complementing the previously granted Indian patent. Through this, MRPL achieved a significant breakthrough in pharmaceutical ingredient synthesis by successfully developing an innovative technology for i-BB production.
This pioneering process involves the side-chain alkylation of an aromatic moiety from a low-value captive stream, facilitated by a newly engineered catalyst developed at MRPL's Innovation Centre. The catalyst is meticulously designed for high conversion rates and outstanding selectivity towards the desired i-BB product. Iso-Butyl Benzene is a critical intermediate in the synthesis of Brufen, a widely used analgesic drug. By developing this technology indigenously, MRPL reduces dependence on imported materials and strengthens its contribution to the domestic pharmaceutical sector. This advancement underscores MRPL's ongoing commitment to research, innovation, and the development of cutting-edge technologies, enhancing India's pharmaceutical manufacturing capabilities. Currently, MRPL is setting up a pilot plant for i-BB production, a key step towards commercial-scale production.
Mangalore Refinery and Petrochemicals is Category 1 Miniratna Central Public Sector Enterprise (CPSE) under the Ministry of Petroleum & Natural Gas. The company is engaged in the business of refining of crude oil.
| Company Name | CMP |
|---|---|
| Reliance Industries | 1346.95 |
| Indian Oil Corp. | 144.50 |
| BPCL | 309.60 |
| HPCL | 368.70 |
| MRPL | 176.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: